By: Laura Baisas From: popsci.com The vaccine targets triple negative breast cancers which make up about 10 to 15 percent of all breast cancers. Researchers at Cleveland Clinic launched their next step in a study of a vaccine aimed at preventing triple-negative breast cancer. Triple-negative breast cancer is the most aggressive and lethal form of the disease, and accounts for …
Breast cancer vaccine safely generates anti-tumor immunity
By: Michael McCarthy. From: newsroom.uw.edu Study findings suggest that a vaccine could be used to prevent or treat a particularly aggressive form of breast cancer. An experimental vaccine against breast cancer safely generated a strong immune response to a key tumor protein, researchers from the University of Washington School of Medicine in Seattle report in a paper published by the journal …
Vaccine designed to prevent triple-negative breast cancer undergoes phase 1 trial
By: Jennifer Byrne From: healio.com Researchers at Cleveland Clinic have initiated a first-of-its-kind study of a vaccine designed to ultimately prevent triple-negative breast cancer — the deadliest form of the disease. The phase 1 study will determine the maximum tolerated dose of the vaccine in patients with early stage, triple-negative breast cancer and evaluate immune response to the vaccine. The …
University of Miami looking for volunteers in breast cancer vaccine study
From: winknews.com The University of Miami is looking for women willing to enroll in its clinical trial for a study on preventing the recurrence of triple negative breast cancer. That form of the cancer has limited treatment options and is likely to come back. The study hopes a vaccine can train the immune system to kill cancerous cells before they …
John Theurer Cancer Center Launches Clinical Trial of Personalized Cancer Vaccine Using New Gene-Based Technology for High-Risk Melanoma
From: PR Newswire Researchers hope the vaccine, combined with immunotherapy, can reduce the risk of relapse in patients after melanoma surgery John Theurer Cancer Center at Hackensack University Medical Center is the only site in New Jersey and one of just 17 in the country participating in a multicenter international Phase II study of an innovative personalized cancer vaccine being …
Moderna ships first batch of COVID-19 vaccine for Phase I trial; study page posted online
By: Alaric DeArment From: medcitynews.com The company said it had shipped the first batch of the vaccine, mRNA-1273, for the NIH-run clinical trial. The study has an estimated start date of March 6, according to ClinicalTrials.gov, while The Wall Street Journal reported it would start in April. A biotech company that is one of several developing vaccines and drugs for …
How a Trial Vaccine Helped Wipe Out a Woman’s Breast Cancer in 7 Months
By: Korin Miller From: prevention.com Florida woman Lee Mercker is recovering well in less than a year after undergoing a new trial vaccine for her breast cancer. Mercker had a very early form of breast cancer and the vaccine was designed to target and kill cancer cells. She was treated at the Mayo Clinic. Cancer doctors and researchers explain how …
Mayo Breast Cancer Vaccine Could Be Available In Less Than A Decade
By: Robin Seaton Jefferson From: forbes.com Researchers at Mayo Clinic in Jacksonville, Florida say a vaccine they have developed could be available within eight years that may not only stop the recurrence of breast and ovarian cancers, but prevent them from developing in the first place. “It is reasonable to say that we could have a vaccine within eight years …
New Colorectal Cancer Vaccine May Help Pancreatic Patients Too
By: Ivanhoe Newswire From: nbcdfw.com Surgery and chemotherapy have long been the primary treatment options for colorectal cancer. Even then, survival rates can be low, if the cancer is not detected early. Now, researchers are fighting back with a simple vaccine meant to activate the body’s immune cells and destroy cancer cells. There is hope it might also target other …
Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer
By: Alice Melão From: breastcancer-news.com The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life Sciences, NeuVax’s developer, has announced. Top-line data from the trial is expected by the end of 2019. “The completion of enrollment of this Phase 2 clinical …
- Page 1 of 2
- 1
- 2